Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 25, Number 3—March 2019

Synopsis

University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018

Heidi M. SoetersComments to Author , Lucy A. McNamara, Amy E. Blain, Melissa Whaley, Jessica R. MacNeil, Susan Hariri, Sarah A. Mbaeyi, and for the Serogroup B Meningococcal Disease University Outbreak Group
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 1

University-based outbreaks of meningococcal disease caused by serogroup B, United States, 2013–2018

State of university
 Outbreak period
 No. cases (deaths)
 Approximate no. undergraduates
 Clonal complex of outbreak strain
 Sequence type of outbreak strain
 References
New Jersey 2013 Mar–2014 Mar 9 (1)* 5,000 41/44 409 (15,16)
California 2013 Nov 4† 19,000 32 32 (17)
Rhode Island 2015 Jan–Feb 2 3,700 Unassigned 9069 (18–21)
Oregon 2015 Jan–May 7 (1)‡ 20,000 32 32 (22,23)
California 2016 Jan–Feb 2§ 5,000 32 11910 (24)
New Jersey 2016 Mar–Apr 2 35,000 11 11 (25)
Wisconsin 2016 Oct 3 30,000 32 11556 (26,27)
Oregon 2016 Nov–2017 Nov 5 25,000 32 32 (28)
Massachusetts¶ 2017 Oct–2018 Feb 3 26,000 41/44 41 (29)
Pennsylvania 2017 Nov 2# 3,600 32** 8758**

*Two of the cases occurred in close contacts of undergraduate students at the outbreak-affected university: 1 in a high school student who stayed in an undergraduate dormitory and 1 in a student at a different university.
†One additional associated case that occurred in March 2013 was identified after retrospective case review. An additional case occurred 2 years later in a close contact of an undergraduate student who may have been connected to this outbreak.
‡One case occurred in a close contact of undergraduate students at the outbreak-affected university.
§One additional suspected case with inconclusive lab results occurred in February 2016 in a student previously vaccinated with 2 doses of MenB vaccine and who received antimicrobial chemoprophylaxis the day before symptom onset.
¶Cases occurred at 2 universities in a college consortium in the same geographic area. The first 2 cases occurred at University 1 and the third case occurred at University 2.
#Cases were close contacts and members of the same athletic team.
**An isolate was available for only 1 of the 2 cases, so typing results refer to the single case isolate.

Main Article

References
  1. MacNeil  JR, Blain  AE, Wang  X, Cohn  AC. Current epidemiology and trends in meningococcal disease—United States, 1996–2015. Clin Infect Dis. 2018;66:1276–81. DOIPubMedGoogle Scholar
  2. Committee on Infectious Diseases, American Academy of Pediatrics, Kimberlin DW, Brady MT, Jackson MA, Long SS. Meningococcal infections. Itasca (IL): American Academy of Pediatrics; 2018 [cited 2018 Nov 13]. https://redbook.solutions.aap.org/chapter.aspx?sectionid=189640131&bookid=2205
  3. Centers for Disease Control and Prevention. Meningococcal disease surveillance. 2018 [cited 2018 Nov 13]. https://www.cdc.gov/meningococcal/surveillance/index.html
  4. Mbaeyi  SA, Blain  A, Whaley  MJ, Wang  X, Cohn  AC, MacNeil  JR. Epidemiology of meningococcal disease outbreaks in the United States, 2009–2013. [Epub 2018 Jun 30]. Clin Infect Dis. 2018.DOIPubMedGoogle Scholar
  5. Cohn  AC, MacNeil  JR, Clark  TA, Ortega-Sanchez  IR, Briere  EZ, Meissner  HC, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1–28.PubMedGoogle Scholar
  6. Food and Drug Administration. Bexsero US package insert. Washington (DC): The Administration; 2015 [cited 2018 Oct 9]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM431447.pdf
  7. Food and Drug Administration. Trumenba US package insert. Washington (DC): The Administration; 2014 [cited 2018 Oct 9]. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM421139.pdf
  8. MacNeil  JR, Rubin  L, Folaranmi  T, Ortega-Sanchez  IR, Patel  M, Martin  SW. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:1171–6. DOIPubMedGoogle Scholar
  9. Folaranmi  T, Rubin  L, Martin  SW, Patel  M, MacNeil  JR; Centers for Disease Control (CDC). Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–12.PubMedGoogle Scholar
  10. Patton  ME, Stephens  D, Moore  K, MacNeil  JR. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine—Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:509–13. DOIPubMedGoogle Scholar
  11. Jackson  LA, Schuchat  A, Reeves  MW, Wenger  JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA. 1995;273:383–9. DOIPubMedGoogle Scholar
  12. Centers for Disease Control and Prevention. Meningococcal disease and college students. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000;49(RR-7):13–20.PubMedGoogle Scholar
  13. Walker  TY, Elam-Evans  LD, Yankey  D, Markowitz  LE, Williams  CL, Mbaeyi  SA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:909–17. DOIPubMedGoogle Scholar
  14. Centers for Disease Control and Prevention. Guidance for the evaluation and public health management of suspected outbreaks of meningococcal disease. 2017 [cited 2018 Oct 9]. https://www.cdc.gov/meningococcal/downloads/meningococcal-outbreak-guidance.pdf
  15. McNamara  LA, Shumate  AM, Johnsen  P, MacNeil  JR, Patel  M, Bhavsar  T, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135:798–804. DOIPubMedGoogle Scholar
  16. Basta  NE, Mahmoud  AA, Wolfson  J, Ploss  A, Heller  BL, Hanna  S, et al. Immunogenicity of a meningococcal B vaccine during a university outbreak. N Engl J Med. 2016;375:220–8. DOIPubMedGoogle Scholar
  17. Breakwell  L, Vogt  TM, Fleming  D, Ferris  M, Briere  E, Cohn  A, et al. Understanding factors affecting university A students’ decision to receive an unlicensed serogroup B meningococcal vaccine. J Adolesc Health. 2016;59:457–64. DOIPubMedGoogle Scholar
  18. Soeters  HM, Whaley  M, Alexander-Scott  N, Kanadanian  KV, MacNeil  JR, Martin  SW, et al.; Rhode Island Meningococcal Carriage Evaluation Team. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college—Rhode Island, 2015–2016. Clin Infect Dis. 2017;64:1115–22. DOIPubMedGoogle Scholar
  19. Soeters  HM, McNamara  LA, Whaley  M, Wang  X, Alexander-Scott  N, Kanadanian  KV, et al.; Centers for Disease Control (CDC). Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:606–7.PubMedGoogle Scholar
  20. Fiorito  TM, Bornschein  S, Mihalakos  A, Kelleher  CM, Alexander-Scott  N, Kanadanian  KV, et al. Rapid response to a college outbreak of meningococcal serogroup B disease: Nation’s first widespread use of bivalent rLP2086 vaccine. J Am Coll Health. 2017;65:294–6. DOIPubMedGoogle Scholar
  21. Fiorito  TM, Baird  GL, Alexander-Scott  N, Bornschein  S, Kelleher  C, Du  N, et al. Adverse events following vaccination with bivalent rLP2086 (Trumenba®): an observational, longitudinal study during a college outbreak and a systematic review. Pediatr Infect Dis J. 2018;37:e13–9.PubMedGoogle Scholar
  22. Fisher  EA, Poissant  T, Luedtke  P, Leman  R, Young  C, Cieslak  P. Evaluation of mass vaccination clinics in response to a serogroup B meningococcal disease outbreak at a large, public university—Oregon, 2015. J Adolesc Health. 2018;63:151–6. DOIPubMedGoogle Scholar
  23. McNamara  LA, Thomas  JD, MacNeil  J, Chang  HY, Day  M, Fisher  E, et al.; Oregon Meningococcal Carriage Team. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak—Oregon, 2015–2016. J Infect Dis. 2017;216:1130–40. DOIPubMedGoogle Scholar
  24. Biswas  HH, Han  GS, Wendorf  K, Winter  K, Zipprich  J, Perti  T, et al. Notes from the field: outbreak of serogroup B meningococcal disease at a University—California, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:520–1. DOIPubMedGoogle Scholar
  25. Soeters  HM, Dinitz-Sklar  J, Kulkarni  PA, MacNeil  JR, McNamara  LA, Zaremski  E, et al. Serogroup B meningococcal disease vaccine recommendations at a university, New Jersey, USA, 2016. Emerg Infect Dis. 2017;23:867–9. DOIPubMedGoogle Scholar
  26. Ritscher  AM, Ranum  N, Malak  JD, Ahrabi-Fard  S, Baird  J, Berti  AD, et al. Meningococcal serogroup B outbreak response University of Wisconsin-Madison. J Am Coll Health. 2018;1–6. DOIPubMedGoogle Scholar
  27. Schauer  S. A serogroup B meningococcal disease outbreak on a Wisconsin university campus and the mass vaccine campaign response—communication. Presented at: 48th National Immunization Conference; 2018 May 15–17; Atlanta, GA, USA.
  28. Haubenreiser  J, Dunn  A. Managing meningococcal disease outbreaks in the university setting: Oregon State University and the State of Oregon Partnership and Response. Presented at: 48th National Immunization Conference; 2018 May 15–17; Atlanta, GA, USA.
  29. Becker  A. Meningitis on campus: reaching students during a meningitis-B outbreak. Presented at: 23rd Annual Massachusetts Adult Immunization Conference; 2018 Apr 10; Marlborough, MA, USA.
  30. Mbaeyi  SA, Joseph  SJ, Blain  A, Wang  X, Hariri  S, MacNeil  JR. Meningococcal disease among college-aged young adults: 2014–2016. Pediatrics. 2019;143:e20182130. DOIPubMedGoogle Scholar
  31. Jolley  KA, Maiden  MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics. 2010;11:595. DOIPubMedGoogle Scholar
  32. MacDougall  DM, Langley  JM, Li  L, Ye  L, MacKinnon-Cameron  D, Top  KA, et al.; Canadian Immunization Research Network. Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination program. Vaccine. 2017;35:2520–30. DOIPubMedGoogle Scholar
  33. Vyse  A, Ellsbury  G, Madhava  H. Protecting UK adolescents and adults against meningococcal serogroup B disease. Expert Rev Vaccines. 2018;17:229–37. DOIPubMedGoogle Scholar
  34. Oliver  S. Meningococcal vaccine policies among colleges and universities—United States, 2017. Presented at: 48th National Immunization Conference; 2018 May 15–17; Atlanta, GA, USA.
  35. Mandal  S, Wu  HM, MacNeil  JR, Machesky  K, Garcia  J, Plikaytis  BD, et al. Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States. Clin Infect Dis. 2013;57:344–8. DOIPubMedGoogle Scholar

Main Article

1Members of the group are listed at the end of this article.

Page created: February 19, 2019
Page updated: February 19, 2019
Page reviewed: February 19, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external